Zebra's revenue and earnings beat expectations; Leslie's Inc. withdraws outlook amid liquidity concerns.

Zebra Technologies saw accelerated revenue growth and better-than-expected margins and earnings across various markets. Bio-Rad Laboratories reported improved demand and announced a restructuring plan to boost profitability. In contrast, Leslie's Inc. withdrew its full-year financial outlook and is exploring strategic options due to rising concerns about liquidity and debt levels. Ariel Fund's Q3 2026 performance slightly lagged the Russell 2500 Value Index but outperformed the Russell 2000 Value Index, reflecting mixed results across its holdings.

Following Ariel Fund's mixed Q3 2026 results, Bio-Rad Laboratories shares are trading at USD 372.71 with a modest 0.75% gain as of Oct 26, 2026 23:21 WIB on Pluang. Meanwhile, Charles River Laboratories, another health sector holding, shows a stronger 1-day increase of 2.52%, priced at USD 354.07. These movements highlight varied investor responses within the fund's health sector stocks.